8-K: Arbutus Biopharma Presents Promising HBV Cure Data

Arbutus Biopharma Corporation has released an updated corporate presentation detailing advancements in its Hepatitis B functional cure programs, particularly focusing on imdusiran's clinical trial results and the development of its oral PD-L1 inhibitor, AB-101.

Summary

• Arbutus Biopharma Corporation posted an updated corporate presentation on November 12, 2026.
• The presentation focuses on the company's strategy to develop a functional cure for chronic Hepatitis B (cHBV).
• Key data from the Phase 2a trials of imdusiran, an siRNA therapeutic, are highlighted, showing meaningful reductions in HBsAg and HBV DNA, with some patients achieving functional cure and discontinuing therapy.
• Imdusiran demonstrated generally safe and well-tolerated profiles in clinical trials involving over 250 patients.
• The company is evaluating development plans for a Phase 2b clinical trial of imdusiran.
• Progress is also reported on AB-101, an oral small molecule PD-L1 inhibitor, with Phase 1 trial data showing target engagement and a favorable safety profile.
• Arbutus Biopharma reported having $104.6 million in cash and cash equivalents as of October 31, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, highlighting promising clinical data for imdusiran and progress with AB-101, though significant hurdles remain in drug development and market penetration.

Positives

• Imdusiran achieved durable viral suppression and functional cures in some patients in Phase 2a trials, with a significant percentage able to discontinue NA therapy.
• Imdusiran demonstrated a generally safe and well-tolerated profile across clinical trials involving over 250 patients, with no drug-related SAEs or safety-related discontinuations in repeat-dose studies.
• The oral PD-L1 inhibitor, AB-101, showed dose-dependent target engagement (up to 100% PD-L1 occupancy at 40 mg) and a favorable pharmacokinetic profile supporting once-daily dosing in Phase 1 trials.
• AB-101 has a potentially superior safety profile compared to IV-administered monoclonal antibody checkpoint inhibitors.
• The company maintains a strong financial position with $104.6 million in cash and cash equivalents as of October 31, 2026.
• Imdusiran demonstrated steep and durable declines in HBV DNA, achieving full HBV DNA suppression significantly faster than NA therapy alone.
• Long-term follow-up data shows remarkable durability of clinical benefits for imdusiran, with patients maintaining functional cure or remaining off NA therapy for extended periods (up to 146+ weeks).

Negatives

• While promising, the functional cure rates for imdusiran in Phase 2a trials were achieved in a subset of patients (e.g., 46% achieved functional cure or discontinued NA therapy across Phase 2a patients).
• The development of imdusiran and AB-101 is still in clinical trial phases, with significant regulatory and commercialization hurdles ahead.
• The presentation acknowledges that ongoing and anticipated clinical trials may be more costly or take longer than anticipated and may not generate results warranting future development.
• Risks related to sufficiency of cash resources are mentioned, although the current cash balance appears adequate for near-term operations.

Risks

• Ongoing and anticipated clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development.
• Results observed in prior clinical trials may not be replicated in larger or later-stage clinical trials.
• Interpretations of clinical data may not be accepted by regulatory authorities.
• Changes in strategy regarding product candidates and clinical development activities may occur.
• The company may not receive the necessary regulatory approvals for its products.
• Economic and market conditions may worsen.
• Market shifts may require a change in strategic focus.
• Risks related to the sufficiency of Arbutus' cash resources are noted.

Future Outlook

The company is evaluating development plans for a Phase 2b clinical trial of imdusiran, including ways to accelerate development. Further clinical trials for AB-101 are also anticipated.

Management Comments

• The company's team includes leaders with the deep scientific and development expertise needed to accelerate and strengthen its portfolios path to market.
• Arbutus is focused on developing a functional cure for patients with chronic Hepatitis B.
• Imdusiran provides meaningful reductions in HBsAg and HBV DNA, leading to functional cure and discontinuation of therapy in some patients, while being generally safe and well-tolerated.

Industry Context

StockSavvy.ai notes that the chronic Hepatitis B market is substantial, with approximately 240 million people affected globally and current treatments offering limited curative potential. Arbutus' focus on a functional cure aligns with a significant unmet medical need, and their progress with imdusiran and AB-101 positions them in a competitive landscape aiming to address this global health challenge.

Comparison to Industry Standards

• Current treatment options for cHBV, including NA therapy and PEG-IFN, show significantly lower rates of HBsAg seroclearance and functional cure compared to the potential demonstrated by imdusiran in clinical trials.
• For example, NA therapy typically requires lifelong treatment with low functional cure rates (e.g., ~2-5% at 3 years). PEG-IFN shows around 19% HBsAg seroclearance at 24 weeks but has tolerability issues.
• Bepirovirsen (Hibsago), approved in October 2026, has a boxed warning and limited efficacy for patients with high baseline HBsAg, whereas imdusiran has shown reductions across various baseline levels.
• Imdusiran's combination therapy results in IM-PROVE I (37% functional cure or NA discontinuation) and IM-PROVE II (52% functional cure or NA discontinuation) suggest a potentially improved outcome compared to monotherapies or other combination approaches.
• The oral administration and safety profile of AB-101 are differentiated from existing IV-administered PD-1/PD-L1 inhibitors, aiming for a better patient experience and potentially fewer immune-related adverse events.

Legal Proceedings

• Risks related to patent litigation matters are mentioned in the forward-looking statements.

Stakeholder Impact

• Shareholders: Positive outlook due to promising clinical data and strong cash position, but development risks remain.
• Patients: Potential for improved treatment options and a functional cure for chronic Hepatitis B, with imdusiran offering a potentially safer and more convenient regimen.
• Healthcare Providers: Introduction of novel therapies that could change the standard of care for cHBV.

Next Steps

• Evaluating development plans for a Phase 2b clinical trial of imdusiran, including ways to accelerate development.
• Continuing clinical trials for AB-101, including Phase 1b trials in cHBV patients.

Key Dates

Recommendation

The presentation shows encouraging progress in clinical development for imdusiran and AB-101, with positive data on efficacy and safety. However, the company is still in the clinical trial phase, facing significant regulatory and commercialization risks. The current cash position is adequate, but further funding may be required. Therefore, a 'hold' recommendation is appropriate, awaiting further clinical data and regulatory milestones.

Keywords

Hepatitis B, chronic Hepatitis B, functional cure, imdusiran, siRNA, PD-L1 inhibitor, AB-101, clinical trials